Information:
Error:
ID
13240
Description
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG; ODM derived from: https://clinicaltrials.gov/show/NCT00061425
Link
https://clinicaltrials.gov/show/NCT00061425
Keywords
Versions (1)
- 1/25/16 1/25/16 -
Uploaded on
January 25, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Non-Hodgkin's Lymphoma NCT00061425
Eligibility Non-Hodgkin's Lymphoma NCT00061425
- StudyEvent: Eligibility
Similar models
Eligibility Non-Hodgkin's Lymphoma NCT00061425
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
b-cell lymphoma, chemotherapy
Item
histological or cytological diagnosis of b-cell lymphoma, and has failed at least one regimen of standard chemotherapy. (all histological grades of nhl will be eligible for this trial.)
boolean
C0079731 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0392920 (UMLS CUI [2])
measureable
Item
measureable via ct, with at least one lesion > or = 1.5cm in one or both dimensions. (splenic tumors in absence of other tumors will not qualify.)
boolean
C1513041 (UMLS CUI [1])
radiologic exam
Item
radiological studies (ie - ct) must be performed within 4 weeks prior to study start.
boolean
C2985535 (UMLS CUI [1])
follow-up, evaluation
Item
acceptable tumor burden that will allow adequate follow-up and evaluation.
boolean
C1522577 (UMLS CUI [1])
C0220825 (UMLS CUI [2])
C0220825 (UMLS CUI [2])
bone marrow
Item
less that 25% bone marrow involvement, determined by bone marrow biopsy.
boolean
C0005953 (UMLS CUI [1])
major surgery, radiation therapy
Item
at least 4 weeks beyond any major surgery. at least 4 weeks beyond any radiation therapy to the index lesion, and has recovered from radiation-induced toxicity.
boolean
C0679637 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C1522449 (UMLS CUI [2])
chemotherapy, immunotherapy, corticosteroids
Item
at least 4 weeks beyond chemotherapy and/or immunotherapy. at least 2 weeks beyond corticosteriod(s) use and blood counts are with laboratory criteria.
boolean
C0392920 (UMLS CUI [1])
C0021083 (UMLS CUI [2])
C0001617 (UMLS CUI [3])
C0021083 (UMLS CUI [2])
C0001617 (UMLS CUI [3])
karnofsky
Item
must have karnofsky score >70% (or equivalent, ecog 0-2) with expected survival of at least 6 months.
boolean
C0206065 (UMLS CUI [1])
creatinine, creatinine clearance
Item
serum creatinine < or = 1.5mg/dl or creatinine clearance > or = 50ml/min.
boolean
C0201976 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
C0373595 (UMLS CUI [2])
bilirubin
Item
serum bilirubin < or = 2mg/dl.
boolean
C1278039 (UMLS CUI [1])
hemoglobin, granulocyte count, transfusions, cytokines
Item
hemoglobin > or = 10 g/dl; wbc > or = 3000/mm3; granulocyte count > or = 150/mm3; platelet count > or = 100,000/mm3 with out transfusions or cytokines for at least 30 days prior to study.
boolean
C0518015 (UMLS CUI [1])
C0857490 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C1879316 (UMLS CUI [4])
C0199974 (UMLS CUI [5])
C0857490 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C1879316 (UMLS CUI [4])
C0199974 (UMLS CUI [5])
human anti-human antibodies
Item
immunomedics elisa assay of hahll2 < 100ng/ml for those with prior history of monoclonal antibody infusions.
boolean
C3641682 (UMLS CUI [1])
informed consent
Item
cognizant informed consent.
boolean
C0021430 (UMLS CUI [1])